Neurology® Podcast

By American Academy of NeurologyScience Medicine Health & Fitness

Favorites
264
Followers
Typical duration
22 min
per episode

Based on Podcast App listening data

Neurology® Podcast episodes

March 11, 2019 A multicentre comparison of MOG-IgG cell based assays
1. A multicentre comparison of MOG-IgG cell based assays. 2. [What's Trending]: the DEFUSE 3 study.

In the first segment, Dr. Stacey Clardy talks with Dr. Paddy Waters about his paper on a multicentre comparison of MOG-IgG cell based assays. In the second part of the podcast, Dr. Andrew Southerland focuses his interview with Dr. Adam de Havenon on the DEFUSE 3 study.

CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
26 min
March 04, 2019 The prevalence of MS in the United States: A population-based estimate using health claims data
1. The prevalence of MS in the United States: A population-based estimate using health claims data.

2. [What's Trending]: Neurology on the Hill and advocacy issue. In the first segment, Dr. Stacey Clardy talks with Dr. Mitch Wallin about his paper examining a population-based estimate on the prevalence of MS in the United States. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Nick Johnson on Neurology on the Hill and advocacy issues.

CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
23 min
February 25, 2019 Quality Improvement in Neurology: Universal Neurology Quality Measurement Set Executive Summary
1. Quality Improvement in Neurology: Universal Neurology Quality Measurement Set Executive Summary2. [What's Trending]: The 2018 report of the Lancet Countdown on health and climate change: shaping the health of nations for centuries to come. In the first segment, Dr. Stacey Clardy talks with Dr. Wayne Anderson and Dr. Justin Martello about their paper on quality improvement in neurology. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Nick Watts on health and climate change shaping the health of nations for centuries to come. DISCLOSURES: Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Wayne Anderson reports no disclosures. Dr. Justin Martello has received travel funding or speaker honoraria from 1) Teva, cash, (2) Abbvie, cash, (3) Lundbeck, cash and is a member of the AAN's Quality and Safety Subcommittee. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
28 min
February 18, 2019 Physical activity, common brain pathologies, and cognition in community-dwelling older adults
1.Physical activity, common brain pathologies, and cognition in community-dwelling older adults 2. [What's Trending]: Deep space medicine. In the first segment, Dr. Jeff Burns talks with Dr. Aron Buchman about his paper on physical activity, common brain pathologies, and cognition in community-dwelling older adults. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Alejandro Rabinstein on the medicine of deep space. Dr. Jeff Burns has served on the DSMB for three NIH-funded trials; has received honorarium and travel for speaking at an Astra-Zeneca symposium; has served on the editorial board of Journal of Alzheimer's Disease; has served as a consultant for protocol development for Stage 2 Innovations; has received commercial research support from Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, vTv Therapeutics, Janssen, and Roche and for investigator-initiated studies from Eli Lilly and Astra-Zeneca; has received governmental research support from the National Institutes of Health; and has provided expert witness testimony in legal cases. Dr. Aron Buchman has received government research support from the National Institutes of Health. Dr. Jason Crowell reports no disclosures. Dr. Alejandro Rabinstein has served as a member of the external committee for adverse event adjudication for PREVAIL trial/CAP2 registry; has served on the editorial boards of Neurology, Neurocritical Care, Stroke, CONTINUUM , and UpToDate; and has received publishing royalties from Elsevier and Oxford.
23 min
February 11, 2019 February 12 2019 Issue
1.Quality of Life Outcomes in Patients Presenting for Evaluation of Central Nervous System Tumors 2. [What's Trending]: 'Landmark study' shows brain cells revamp their DNA, perhaps sparking Alzheimer's disease. In the first segment, Dr. Ted Burns talks with Dr. Irene Katzan about her paper on quality of life outcomes in patients presenting for evaluation of central nervous system tumors. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Jerold Chun on a 'Landmark study' showing brain cells revamp their DNA, perhaps sparking Alzheimer's disease.Dr. Ted Burns has served on scientific advisory boards for Argenx, Momenta, received travel funding or speaker honoraria from Argenx, Alexion and received support for consulting activities from UCB Pharma, CSL Behring, Momenta, Argenx. Dr. Irene Katzan has served on editorial boards for Stroke (American Stroke Association), 2014-present Editorial Board - Circulation: Cardiovascular Quality & Outcomes (American Heart Association) 2013 – present. Dr. Irene Katzan has received research from one commercial entity including Novartis Pharmaceuticals and received research support from the following government entity: Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Jerold Chun reports no disclosures.
21 min
February 04, 2019 February 5 2019 Issue
1. Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program 2. [What's Trending]: Mapping Symptoms to Brain Networks with the Human Connectome. In the first segment, Dr. Teshamae Monteith talks with Dr. Roy Hamilton about his paper on reducing neurodisparity. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Michael D. Fox on mapping symptoms to brain networks with the human connectome.DISCLOSURES Dr. Teshamae Monteith has served on Scientific Advisory Boards for Lilly, Supernus, Teva, Electrocore, Promius and is an editorial advisory board member for Neurology. Dr. Roy Hamilton has served without compensation on the scientific advisory board for an NIH-funded R21 project titled ""Combining tDCS and neurorehabilitation to treat age-related deficits of mobility and cognition (UPfront Walking Study) as the data safety monitor. Dr. Hamilton has served on editorial boards for (1)Cognitive and Behavioral Neurology, editorial board member, and (2)Restorative Neurology and Neuroscience, editorial board member, 2011 to present. Dr. Hamilton is employed by Neuronix LTD as a Medical consultant, 2014 to present. Dr. Hamilton has done consultancies for Geurbet Ltd. on the development of an FDA-mandated clinical trial and received approximately $6000 for work in the last 2 years (2017-18). Dr. Hamilton received research support from 1) NIH/NIA 5P30-AG-010124-27 Co-Investigator 7/15/97-6/30/19 2) NIH/NIDCD 1 R01 DC012780-01A1 Principal Investigator 7/01/2013 - 6/30/2019 3) NIH/NIDCD 2-R01-DC-009209-11 Co-Investigator 6/01/2014 - 5/31/2019 4) NIH/NIDCR DP5OD021352 Co-Investigator 9/19/2015 - 08/31/2020 5) NIH/NIDCD 1R01DC015359-01A1 Co-Investigator 4/01/2016 - 3/31/2021 6) University of Pennsylvania/Translational Neuroscience Initiative (TNI) Co-Investigator 7/01/2016 - 6/30/2019 . 7) NIH/NEI R01EY022350 Co-Investigator 9/01/2016 - 8/31/2021 8) NIH/NINDS 5P30NS045839-12 Co-Investigator 2/1/2014-1/31/2018 9) Templeton Foundation/Imagination Institute Principal Investigator 7/01/2015 – 6/30/2017 10) Association for Frontotemporal Dementia Principal Investigator 1/01/2016 – 12/31/2016 11) Dana Foundation Principal Investigator 12/13/2012 - 4/24/2018. Dr. Hamilton's legal proceedings include Kline & Specter Attorneys at Law, Consultant, 2014, 2015. Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Michael D. Fox has patents issues or submitted using brain imaging to guide brain stimulation. Dr. Fox has done consultancies for Mint Labs and has received research support from one government entity (1) NIH, K23NS083741 and research support from two foundations and societies (1) Dystonia Medical Research Foundation (2) National Parkinson's Foundation.
28 min
January 28, 2019 January 29 2019 Issue
1. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement. 2. [What's Trending]: On tau protein and Alzheimer dementia symptoms. In the first segment, Dr. Jason Crowell talks with Dr. James Russell about his paper on brain death, the determination of brain death, and member guidance for brain death accommodation requests. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Matthew Brier on tau protein and Alzheimer dementia symptoms.DISCLOSURES: Dr. Jason Crowell reports no disclosures. Dr. James Russell has served on Scientific Advisory Boards for Cytokinetics - Data Monitoring Board PROTOCOL CY 5022 A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE- RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). Dr. James Russell received travel funding from 1) Non-profit - Mexican Academy of Neurology - Funded travel and lodging to speak at Annual Meeting Nov 2018 - no honorarium (2) Non-profit - ALS Association - funded travel and lodging to do site visit for ALSA certification of UVA ALS Clinic. Dr. James Russell has publishing royalties from (1) Neuromuscular Disorders, McGraw-Hill, 2nd edition published 2015, with subsequent royalities 2) Honorarium for published article in Continuum: Approach to peripheral neuropathy. Continuum: Peripheral Nervous System Disorders. Fall 2017. Dr. James Russell has done consultancies with compensation for market research interviews regarding ALS therapeutics and is currently being compensated for expert opinion in two medical legal cases, one in support of the defendant and one in support of the plaintiff. Dr. Matthew Brier has received funding for Biogen, travel and accommodation and received research support for Medical Scientist Training Program Grant to WUSTL (5T32GM007200-37.
24 min
January 21, 2019 January 22 2019 Issue
1. Aspirin Reduces Long Term Stroke Risk in Women with Prior Hypertensive Disorders of Pregnancy 2. [What's Trending]: Top-selling drug price hikes and patients bearing the cost. In the first segment, Dr. Andrew Southerland talks with Dr. Eliza Miller about her paper on aspirin reducing the long term stroke risk in women with prior hypertensive disorders of pregnancy. In the second part of the podcast, Dr. Ted Burns focuses his talk with Casey Ross on makers of top-selling drugs hiking prices and patients bearing the costs.DISCLOSURES: Dr. Eliza Miller has served on Editorial Boards for Stroke, Assistant Editor, InterSECT, 2017-2018. Dr. Eliza Miller Research Support, Government Entities including (1) NIH NINDS 5U10NS086728-05, Fellow, 2017-2018 (2) NIH NINDS U01 NS095869, Subsite PI, 2018 (3) NIH NCATS 5KL2TR001874-02, KL2 Scholar, 2018-2020 and she has received research support from Foundations and Societies including American Medical Association Foundation and Louis V. Gerstner Foundation. Casey Ross reports no disclosures.
23 min
January 07, 2019 January 8 2019 Issue
1. Development and validation of a score to detect paroxysmal atrial fibrillation after stroke. 2. [What's Trending]: Drug pricing and the Institute for Clinical and Economic Review framework. In the first segment, Dr. Andy Southerland talks with Dr. Timo Uphaus about his paper on the development and validation of a score to detect paroxysmal atrial fibrillation after stroke. In the second part of the podcast, Dr. Gordon Smith focuses his interview with Dr. Steve Pearson on the Institute for Clinical and Economic Review and drug pricing. DISCLOSURES: Dr. Southerland has severed on editorial boards for the Journal Neurology and is Section Editor for the Neurology Podcast. Dr. Timo Uphaus reports no disclosures. Dr. A. Gordon Smith has served on the scientific advisory board of the Regenesis Data Monitoring Committee; has served on the editorial boards for Continuum and Annals of Clinical and Translational Neurology; has served as a consultant for Regenesis; has served on the speakers' bureau for Alexion; has received commercial research support from Impeto Medical SAS; and has received governmental research support from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Neurological Disorders and Stroke. Dr. Steve Pearson's Institute for Clinical and Economic Review has received membership dues from Aetna, Alnylam, America's Health Insurance Plans (AHIP), Anthem, AstraZeneca, Blue Shield of CA, Cambia Health Solution, CVS, Caremark, Editas, Express Scripts, Genentech, GlaxoSmithKline, Harvard Pilgrim Health Care, Health Care Service Corporation (HCSC), HealthPartners, Johnson & Johnson, Kaiser Permanente, Mallinckrodt Pharmaceuticals, Merck & Co., National Pharmaceutical Council (NPC), Novartis, Premera Blue Cross, Prime Therapeutics, Regeneron, Sanofi, and United Healthcare; and has received foundation/society research support from the Laura and John Arnold Foundation, the California Health Care Foundation, Blue Shield of California Foundation, Kaiser, East Bay Community Foundation, and the Commonwealth Fund.
22 min
December 31, 2018 January 1 2019 Issue
1. Continuous EEG is Associated with Favorable Hospitalization Outcomes for Critically Ill Patients. 2. [What's Trending]: Investigation of "generic" cartel. In the first segment, Dr. Andy Schomer talks with Dr. Chloe Hill on the association between continuous EEG and favorable hospitalization outcomes for critically ill patients. In the second part of the podcast, Dr. Ted Burns focuses his interview with Christopher Rowland of the Washington Post on the investigation into a generic drug "cartel." Dr. Chloe Hill has served as an epileptologist for clinical procedures or imaging studies; and has received governmental research support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke. Dr. Ted Burns has served on the scientific advisory boards for Argenx and Momenta; has received funding for travel or speaker honoraria from Argenx and Alexion; has served on editorial boards as the Section Editor for Neurology Podcast and as Section Deputy Editor, Neurology Podcast; and has received support for consulting activities from UCB Pharma, CSL Behring, Momenta, and Argenx. Christopher Rowland is employed as a full-time reporter for the Washington Post.
24 min

About Neurology® Podcast

From the publisher's feed

The Neurology Podcast provides practical information for neurologists and clinicians to practice the best possible medicine for patients. Examining methods and findings in peer-reviewed journals, the…